Cat. No.: HY-120832

Azt-pmap

Customer Review

Based on 1 Customer Validation

Azt-pmap, a nucleoside analogue, is an aryl phosphate derivative of AZT. Azt-pmap shows anti-HIV activity. AZT is a nucleoside reverse transcriptase inhibitor (NRTI) for HIV infection. Azt-pmap is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

For research use only. We do not sell to patients.

Purity: 99.85%
CAS No.: 142629-81-0
Formula: C₂₀H₂₅N₆O₈P
Molecular Weight:508.42

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Azt-pmap Chemical Structure

CAS No.: 142629-81-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Azt-pmap, a nucleoside analogue, is an aryl phosphate derivative of AZT. Azt-pmap shows anti-HIV activity^[1]. AZT is a nucleoside reverse transcriptase inhibitor (NRTI) for HIV infection^[2]. Azt-pmap is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

IC₅₀ & Target^[1]

HIV-1

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	172 μM Compound: 2a	cytotoxic activity in CEM/0 cell line cytotoxic activity in CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	CC₅₀	172 μM Compound: 4 ([PhMeAla]AZT)	Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells. Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	CC₅₀	9.7 x 10^-5M Compound: 4	Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1 Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1	[PMID: 9871705]
CCRF-CEM	EC₅₀	0.055 μM Compound: 2a	Anti HIV-1 activity in human lymphocyte CEM/0 cell line Anti HIV-1 activity in human lymphocyte CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	EC₅₀	0.055 μM Compound: 4 ([PhMeAla]AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	0.07 μM Compound: 2a	Anti HIV-2 activity in human lymphocyte CEM/0 cell line Anti HIV-2 activity in human lymphocyte CEM/0 cell line	[PMID: 8478904]
CCRF-CEM	EC₅₀	0.07 μM Compound: 4 ([PhMeAla]AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	12 μM Compound: 2a	Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase	[PMID: 8478904]
CCRF-CEM	EC₅₀	12 μM Compound: 4 ([PhMeAla]AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	4.1 x 10^-6M Compound: 4	Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1 Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1	[PMID: 9871705]
CEM-SS	CC₅₀	>100 μM Compound: 1	Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line	[PMID: 14521418]
CEM-SS	EC₅₀	0.05 μM Compound: 1	Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line	[PMID: 14521418]
CEM-TK(+)	CC₅₀	>100 μM Compound: 1	Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line	[PMID: 14521418]
JM1	ED₅₀	0.8 μM Compound: 2d	Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control	10.1016/S0960-894X(00)80395-9
MT4	CC₅₀	>10 μM Compound: 1	Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line	[PMID: 14521418]
MT4	CC₅₀	>50 μM Compound: 2a	cytotoxic activity in MT-4 cell line cytotoxic activity in MT-4 cell line	[PMID: 8478904]
MT4	EC₅₀	0.006 μM Compound: 2a	Anti HIV-1 activity in human lymphocyte MT-4 cell line Anti HIV-1 activity in human lymphocyte MT-4 cell line	[PMID: 8478904]
MT4	EC₅₀	0.007 μM Compound: 2a	Anti HIV-2 activity in human lymphocyte MT-4 cell line Anti HIV-2 activity in human lymphocyte MT-4 cell line	[PMID: 8478904]
MT4	EC₅₀	0.34 μM Compound: 1	Effective concentration required to inhibit HIV-1 replication in MT-4 cell line Effective concentration required to inhibit HIV-1 replication in MT-4 cell line	[PMID: 14521418]

In Vitro

Azt-pmap shows anti-HIV-1 activities in infected C8166 and JM cells with EC₅₀s of 0.08 and0.32 μM, respectively. Azt-pmap displays toxicities in infected C8166 and JM cells with TC₅₀s of 500 μM, respectively. Azt-pmap inhibits virus replication^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 142629-81-0
Appearance Solid
Molecular Weight 508.42
Formula C₂₀H₂₅N₆O₈P
Color White to off-white
SMILES

O=C(NC1=O)N(C=C1C)[C@@H]2O[C@H](COP(OC3=CC=CC=C3)(N[C@@H](C)C(OC)=O)=O)[C@@H](N=[N+]=[N-])C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (196.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9669 mL

9.8344 mL

19.6688 mL

5 mM

0.3934 mL

1.9669 mL

3.9338 mL

10 mM

0.1967 mL

0.9834 mL

1.9669 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. McGuigan C, et al. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antiviral Res. 1992 Apr;17(4):311-21. [Content Brief]

[2]. Gray LR, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013 Apr 16;8(4):e62196. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9669 mL	9.8344 mL	19.6688 mL	49.1719 mL
	5 mM	0.3934 mL	1.9669 mL	3.9338 mL	9.8344 mL
	10 mM	0.1967 mL	0.9834 mL	1.9669 mL	4.9172 mL
	15 mM	0.1311 mL	0.6556 mL	1.3113 mL	3.2781 mL
	20 mM	0.0983 mL	0.4917 mL	0.9834 mL	2.4586 mL
	25 mM	0.0787 mL	0.3934 mL	0.7868 mL	1.9669 mL
	30 mM	0.0656 mL	0.3278 mL	0.6556 mL	1.6391 mL
	40 mM	0.0492 mL	0.2459 mL	0.4917 mL	1.2293 mL
	50 mM	0.0393 mL	0.1967 mL	0.3934 mL	0.9834 mL
	60 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8195 mL
	80 mM	0.0246 mL	0.1229 mL	0.2459 mL	0.6146 mL
	100 mM	0.0197 mL	0.0983 mL	0.1967 mL	0.4917 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Azt-pmap

MCE Bioactive Compound Library

All HIV Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Azt-pmap Related Classifications

HY-120832 Related Classifications